Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.’s (“Cabaletta Bio” or “Cabaletta”) (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has been infused into the first two patients using drug product manufactured on Cellares' Cell Shuttle TM automated manufacturing platform. The administration of an autologous cell therapy, which met all release criteria and was manufactured on an